Dasatinib, an immunomodulator?

Research output: Contribution to journalComment/debatepeer-review

5 Scopus citations

Abstract

In this issue of Blood, Kreutzman and colleagues describe the existence of clonal cytotoxic T and NK cells in over 80% (15 of 18) of patients with CML at diagnosis which persisted during treatment with the tyrosine kinase inhibitors, imatinib and dasatinib.1 Furthermore, they discovered that this clonal lymphocytosis expands further after therapy with dasatinib but not imatinib.

Original languageEnglish (US)
Pages (from-to)673-674
Number of pages2
JournalBlood
Volume116
Issue number5
DOIs
StatePublished - Aug 5 2010

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Dasatinib, an immunomodulator?'. Together they form a unique fingerprint.

Cite this